What is the CVSS score of CVE-2018-14787?

CVE-2018-14787 has a CVSS 3.1 base score of 7.8 (High). CVSS vector: CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H. EPSS exploitation probability: 0.4%.

Intellispace Cardiovascular CVE-2018-14787

HIGH

Improper Privilege Management (CWE-269)

2018-08-22 ics-cert@hq.dhs.gov

Privilege Escalation RCE Intellispace Cardiovascular Xcelera

7.8

CVSS 3.1 · NVD

Severity by source

NVD PRIMARY

7.8 HIGH

AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Primary rating from NVD · only source for this CVE.

CVSS VectorNVD

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Attack Vector

Local

Attack Complexity

Low

Privileges Required

Low

User Interaction

None

Scope

Unchanged

Confidentiality

High

Integrity

High

Availability

High

Lifecycle Timeline

CVE Published

Aug 22, 2018 - 18:29 nvd

HIGH 7.8

DescriptionNVD

In Philips' IntelliSpace Cardiovascular (ISCV) products (ISCV Version 2.x or prior and Xcelera Version 4.1 or prior), an attacker with escalated privileges could access folders which contain executables where authenticated users have write permissions, and could then execute arbitrary code with local administrative permissions.

AnalysisAI

In Philips' IntelliSpace Cardiovascular (ISCV) products (ISCV Version 2.x or prior and Xcelera Version 4.1 or prior), an attacker with escalated privileges could access folders which contain. Rated high severity (CVSS 7.8), this vulnerability is low attack complexity. No vendor patch available.

Technical ContextAI

This vulnerability is classified as Improper Privilege Management (CWE-269), which allows attackers to escalate privileges to gain unauthorized elevated access. In Philips' IntelliSpace Cardiovascular (ISCV) products (ISCV Version 2.x or prior and Xcelera Version 4.1 or prior), an attacker with escalated privileges could access folders which contain executables where authenticated users have write permissions, and could then execute arbitrary code with local administrative permissions. Affected products include: Philips Intellispace Cardiovascular, Philips Xcelera. Version information: Version 2..

RemediationAI

No vendor patch is available at time of analysis. Monitor vendor advisories for updates. Apply principle of least privilege, validate privilege transitions, implement proper role separation.